Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Yes, the shingles vaccine substantially lowers your risk, though it does not eliminate it entirely. Shingrix, the recombinant two-dose vaccine recommended for adults 50 and older and for immunocompromised adults 19 and older, is more than 90% effective at preventing shingles and postherpetic neuralgia in healthy adults, with protection remaining above 70% for at least seven to ten years. Effectiveness is somewhat lower in people with weakened immune systems, and factors like your age at vaccination, completing both doses two to six months apart, and prior shingles history all influence how well it works. Several important details, including who should wait, common side effects, and what breakthrough cases look like, are explained below.
If you are noticing a painful, burning, tingling, or blistering rash on one side of your body, timing matters, because antiviral treatment works best within 72 hours of symptoms starting. Take a free, instant, online symptom check to better understand what may be causing your symptoms and what step to take next.
Last reviewed for medical accuracy: 10/01/2026
Shingles (herpes zoster) is a painful rash caused by the reactivation of the chickenpox virus (varicella-zoster virus) in the body. Many people ask, “does the shingles vaccine prevent shingles?” The short answer is yes. Vaccination is the most effective way to reduce your risk of developing shingles and its complications. Below, we’ll explore how well the vaccine works, who should get it, and what to expect.
The shingles vaccine trains your immune system to recognize and fight the varicella-zoster virus, lowering the chance that the dormant virus in your nerve cells will reactivate and cause shingles.
There are two main vaccines:
Shingrix is recommended over Zostavax because it offers stronger and longer-lasting protection with no live virus components, making it safer for people with weakened immune systems.
Several large clinical trials and real-world studies have measured vaccine efficacy. Here’s what they found:
These figures come from the U.S. Centers for Disease Control and Prevention (CDC) and peer-reviewed studies. Overall, Shingrix prevents shingles in over 9 out of 10 people who receive both doses, making it the preferred choice.
The CDC recommends Shingrix for adults 50 years and older, even if you:
Talk to your doctor about timing if you:
Preventing shingles isn’t the only advantage. Vaccination also:
Both vaccines have been studied extensively and have strong safety profiles. Side effects tend to be mild to moderate:
Serious allergic reactions are rare. If you have a history of severe allergy to any vaccine components, speak to your doctor first.
Researchers continue to monitor long-term immunity to guide future recommendations.
No vaccine prevents disease 100% of the time, but Shingrix comes very close. Rare “breakthrough” cases may occur, often with milder symptoms and shorter duration. Overall, widespread vaccination:
If you experience a new, unexplained rash or pain that could indicate shingles, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide if you need prompt medical attention.
Vaccination decisions and symptom concerns can be complex. Always:
By getting vaccinated, you significantly lower your chance of suffering from shingles and its long-term effects. If you have questions or concerns, speak to your doctor to find the best plan for your health.
(References)
* Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices. Hum Vaccin Immunother. 2025 Dec;21(1):2488093. doi: 10.1080/21645515.2025.2488093. Epub 2025 Apr 18. PMID: 40249278; PMCID: PMC12013443.
* Florea A, Wu J, Qian L, Lewin B, Sy LS, Lin IC, Ku JH, Tseng HF. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec;22(1):643-649. doi: 10.1080/14760584.2023.2232451. PMID: 37416973.
* Jones K MD, Keating M DO, MEd, Hansell M MD. Herpes Zoster and Postherpetic Neuralgia: Common Questions and Answers. Am Fam Physician. 2026 Aug;114(2):164-172. PMID: 42789654.
* Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL. Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. Am J Prev Med. 2020 Jul;59(1):21-31. doi: 10.1016/j.amepre.2020.01.017. Epub 2020 May 7. PMID: 32389533; PMCID: PMC9196997.
* Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24. PMID: 22828595; PMCID: PMC4542855.
* Kupa LVK, Medeiros-Ribeiro AC, Aikawa NE, Pasoto SG, Borba EF, Assad APL, Saad CGS, Yuki EFN, Seguro LPC, Andrade D, Shinjo SK, Sampaio-Barros PD, Shimabuco AY, Moraes JCB, Sampaio VS, Giardini HAM, Silva CAA, Bonfá E. Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study. J Clin Rheumatol. 2025 Sep 1;31(6):e104-e111. doi: 10.1097/RHU.0000000000002216. Epub 2025 Mar 4. PMID: 40036115.
* Gatwood J, Gomez-Espinosa E, Fusco N, Stempniewicz N, Singer D. Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States. Vaccine. 2026 Jan 25;71:128015. doi: 10.1016/j.vaccine.2025.128015. Epub 2025 Dec 6. PMID: 41353819.
* Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol. 2017 Jul;44(7):1083-1087. doi: 10.3899/jrheum.160685. Epub 2017 Mar 15. PMID: 28298565; PMCID: PMC5724562.
* Cogman AR, Chakravarty EF. The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine. 2013 Aug 12;31(36):3640-3. doi: 10.1016/j.vaccine.2013.05.085. Epub 2013 Jun 3. PMID: 23742992; PMCID: PMC3952213.
* Morgado-Carrasco D, Fustà-Novell X, Giavedoni P. RF-New Recombinant Vaccine for the Prevention of Herpes Zoster. Actas Dermosifiliogr (Engl Ed). 2020 Jan 2;111(1):67-68. doi: 10.1016/j.ad.2018.06.020. Epub 2019 Aug 3. PMID: 31387689.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.